| Active substance | tepotinib |
| Holder | Merck nv/sa |
| Status | closed |
| Indication | Treatment of adult patients with advanced non-small cell lung cancer harboring mesenchymal-epithelial transition factor gene METexon14 (METex14) skipping alterations. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 03/02/2023 |